BEND, Ore.--(BUSINESS WIRE)--Amplion, developer of BiomarkerBase™, the industry’s leading platform for researching biomarkers in clinical use and development, announces today that BiomarkerBase™ is now the first and only database that includes biomarkers in Laboratory-Developed Tests (LDTs).
“Laboratory-developed tests represent the segment of the testing market where most of the innovation has taken place over the last decade,” said John Audette, CEO of Amplion. “Being able to analyze biomarkers used in LDTs, alongside biomarkers in FDA-approved tests, drug labels, and clinical trials, is a capability our customers in biopharma and diagnostics have been requesting for some time.”
Having just completed indexing the test menu from one of the world’s largest diagnostic test providers, Amplion’s BiomarkerBase™ now gives strategic decision makers access to a vast portion of the biomarker market that has been practically inaccessible until now.
“We knew the addition of LDT menus would expose the next level of innovation in clinical biomarker usage,” said Adam Carroll, PhD, CSO of Amplion, “but we didn’t expect the first test menu to add more than 1,000 new biomarkers.”
What This Unprecedented Data Update Means
With the inclusion of LDTs, 30% more of the newest and most innovative clinical biomarkers are now normalized and readily accessible through the BiomarkerBase™ intuitive interface.
This information, along with every biomarker in an FDA-approved test or drug label and thousands of biomarkers in clinical trials, gives researchers an unprecedented view of the clinical biomarker landscape.
Amplion’s recently released research report titled “Market Trends for Biomarker-Based IVD Tests (2003-2014)” focuses on trends in the development and use of clinical biomarkers. LDTs are a critical part of the market that has been missing from such analyses before now.
Biomarker-based tests are what enable personalized medicine. And now with the addition of LDT information to BiomarkerBase™ researchers, product portfolio managers and market analysts can better understand the full life cycle of personalized patient care from drug and diagnostic development through to diagnosis and therapy.
Remember the last scene from Raiders of the Lost Ark where the Ark of the Covenant becomes lost in a sea of identical wooden crates inside a gigantic warehouse? At Amplion, we liken the Ark of the Covenant to how hugely valuable — but largely inaccessible — biomarker data is currently housed. Sure, it’s there — but good luck finding it.
We want to change that, which is why we created Amplion’s flagship product, BiomarkerBase™, that’s already reinventing translational research for a number of the largest drug and diagnostics companies worldwide.
Based in Bend, Oregon, Amplion is accelerating personalized medicine by making it easier for drug and diagnostic development professionals to both access and analyze information about clinical biomarkers.
Amplion created BiomarkerBase™ to reinvent the translational research landscape. Recognizing that researchers must rely on a manual workflow where crucial information is all too often siloed into single-use studies and presentations that are essentially inaccessible to the wider community.